117007-52-0

Basic information

• Product Name: 3-Iodo-7-aza-1H-azaindazole
• Synonyms: 3-Iodo-7-aza-1H-azaindazole;3-iodo-1H-pyrazolo[3,4-b]pyridine;3-Iodo-;3-Iodo-1H-pyrazolo[3,4-b]...;1H-Pyrazolo[3,4-b]pyridine, 3-iodo-;3-Iodo-7-aza-1H-indazole;3-iodo-2H-pyrazolo[3,4-b]pyridine
• CAS NO: 117007-52-0
• Molecular Formula: C₆H₄IN₃
• Molecular Weight: 245.02
• Product Categories: Aromatics;Heterocycles
• Mol File: 117007-52-0.mol

Chemical Properties

• Melting Point: 177-179°C
• Boiling Point: 379.827 °C at 760 mmHg
• Flash Point: 183.513 °C
• Appearance: /
• Density: 2.22 g/cm³
• Refractive Index: 1.81
• Storage Temp.: -20?C Freezer
• Solubility: Chloroform, DMSO
• PKA: 7.96±0.40(Predicted)
• CAS DataBase Reference: 3-Iodo-7-aza-1H-azaindazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Iodo-7-aza-1H-azaindazole(117007-52-0)
• EPA Substance Registry System: 3-Iodo-7-aza-1H-azaindazole(117007-52-0)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-37/39
• RIDADR: UN2811
• Hazardous Substances Data: 117007-52-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Iodo-7-aza-1H-azaindazole is used as a key intermediate compound for the preparation of azaindazole compounds, which serve as CCR1 antagonists. These antagonists are important in the development of medications targeting various inflammatory and immune disorders, as they help modulate the immune response by blocking the action of chemokine receptors.
The specific application of 3-Iodo-7-aza-1H-azaindazole in the pharmaceutical industry lies in its role as a building block for creating more complex and targeted therapeutic molecules. Its unique structure allows for the development of CCR1 antagonists with improved efficacy and selectivity, potentially leading to more effective treatments for a range of conditions.

InChI:InChI=1/C6H4IN3/c7-5-4-2-1-3-8-6(4)10-9-5/h1-3H,(H,8,9,10)

Upstream product

• 109-09-1 2-chloropyridine 
• 63682-46-2 C₆H₄N₅⁽¹⁺⁾*BF₄^(1-) 
• 6752-16-5 1H-pyrazolo[3,4-b]pyridin-3-amine 
• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 36404-88-3 2-chloro-3-carbaldehydepyridine 
• 271-73-8 1H-Pyrazolo[3,4-b]pyridine 
• 63682-42-8 3-Diazapyrazolo<3,4-b>pyridine 

Downstream Products

• 875781-18-3 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine 
• 1299607-55-8 tert-butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 
• 916326-31-3 tert-butyl 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 
• 956010-88-1 1H-pyrazolo[3,4-b]pyridine-3-carbonitrile 
• 1246520-74-0 C₁₇H₁₅N₃O₃ 
• 1246519-54-9 C₁₈H₁₈N₄O₂ 
• 1246519-62-9 C₁₇H₁₇ClN₄O 
• 1246519-71-0 C₁₉H₂₂N₄O 
• 1246519-76-5 C₁₈H₂₀N₄O₂ 
• 1246519-78-7 C₂₂H₂₇N₅O₃ 
• 916325-84-3 methyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate 

Relevant articles and documents

Synthesis and biological evaluation of novel pyrazolo[3,4-b]pyridines as cis-restricted combretastatin A-4 analogues

Twenty-six novel pyrazolo[3,4-b]pyridine-bridged analogues of combretastatin A-4 possessing 3,4,5-trimethoxylphenyl groups, were synthesized and evaluated for their antiproliferative and tubulin polymerization inhibitory activities. Preliminary biological evaluation demonstrated that some of the target compounds displayed significant antiproliferative effect against four different cell lines including MCF-7, MDA-MB-231, HeLa and Kyse150. The most active analogue 6n was found to induce HeLa cells arrest in the G2/M phase in a dose-dependent manner. Molecular modeling studies indicated that derivative 6n most likely occupies the colchicine site of tubulin. The initial results suggest that the 3,4,5-trimethoxyphenyl substituted pyrazolo[3,4-b]pyridine could serve as a promising scaffold for development of potent tubulin inhibitors as anticancer agents.

Selective C-H Iodination of (Hetero)arenes

Iodoarenes are versatile intermediates and common synthetic targets in organic synthesis. Here, we present a strategy for selective C-H iodination of (hetero)arenes with a broad functional group tolerance. We demonstrate the utility and differentiation to other iodination methods of supposed sulfonyl hypoiodites for a set of carboarenes and heteroarenes.

BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME

Provided is a compound showing excellent antifungal activity against Trichophyton fungus, which is a major causative microorganism of superficial mycosis, and high effectiveness on diseases caused by Trichophyton fungi. A biaryl derivative represented by the formula (I) or a salt thereof: wherein ring A is an optionally substituted phenyl, or an optionally substituted 5- or 6-membered ring heteroaryl (ring A may be further condensed to form an optionally substituted fused ring); Q is CH2, C=O, NH, O, S or the like; X1, X2 and X3 are CR1 or N; Y is CH or N; Z is CR2b or N; R2a and R2b are each a hydrogen atom, a halogen atom, an optionally substituted C1-C6 alkyl group, a C1-C6 haloalkyl group or the like; R2a and R2b may form, together with carbon atoms bonded thereto, an optionally substituted carbocycle, or an optionally substituted heterocycle.

PHARMACEUTICALS COMPRISING BIARYL DERIVATIVES OR SALTS THEREOF

PROBLEM TO BE SOLVED: To provide compounds with excellent antimycotic activity against Trichophyton. SOLUTION: The invention provides pharmaceuticals comprising biaryl derivatives represented by general formula (I) or salts thereof, where ring A is optionally substituted phenyl or the like; Q is CH2 or the like; X1, X2 and X3 are CR1 or the like; and Y is CH or N. SELECTED DRAWING: None COPYRIGHT: (C)2018,JPOandINPIT

PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS

Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Use of 3-(trifluoromethyl)-1H-pyrazolo-[3,4-b]pyridine as a versatile building block

A one-pot multigram synthesis of 3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridine starting from 2-fluoropyridine using directed ortho metallation (DoM) technique is described. The compound contains an anionically activatable trifluoromethyl group and is a versatile building block for the microwave assisted synthesis of 3-substituted 1H-pyrazolo[3,4-b]pyridines.

PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS

The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement alternative inhibitors for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors

A series of 7-azaindazolyl-indolyl-maleimides were designed, synthesized and evaluated for their GSK-3β inhibitory activity. Most compounds exhibited potent activity against GSK-3β. Among them, compounds 17a, 17b, 17g, 17i, 29a and 30 significantly reduced Aβ-induced Tau hyperphosphorylation, showin;g the inhibition of GSK-3β at the cell level. Preliminary structure-activity relationships were discussed based on the experimental data obtained.

INDAZOLEPROPIONIC ACID AMIDE COMPOUND

Disclosed is a compound which is useful in preventing and treating cardiac arrhythmia such as atrial fibrillation. A compound represented by formula (1) or a pharmaceutically acceptable salt of the same. In formula (1), ring X represents benzene or pyridine; R1 represents an optionally substituted alkyl group; R2 represents an optionally substituted aryl group, an optionally substituted heterocyclic group, an optionally substituted arylalkyl group or an optionally substituted heterocyclic group-substituted alkyl group; R3, R4, R5, R6, R7, R8 and R9 represent each hydrogen or an alkyl group, provided that R3 and R5 may be bonded to each other to form, together with the carbon atom adjacent thereto, a cycloalkyl group; and m represents 0 or 1.

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I , or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof